We are live on ! Find out more
OTLK icon

Outlook Therapeutics

66 hedge funds and large institutions have $9.56M invested in Outlook Therapeutics in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

11% more capital invested

Capital invested by funds: $8.64M → $9.56M (+$915K)

5% more funds holding

Funds holding: 6366 (+3)

3.92% less ownership

Funds ownership: 21.72%17.8% (-3.9%)

11% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 18

24% less call options, than puts

Call options by funds: $31K | Put options by funds: $41K

Holders
66
Holders Change
+3
Holders Change %
+4.76%
% of All Funds
0.87%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
16
Reduced
18
Closed
17
Calls
$31K
Puts
$41K
Net Calls
-$10K
Net Calls Change
-$52K

OTLK Hedge Fund Activity: Q2 2025 in Review

66 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2025, worth a combined $9.56M — up 11% from $8.64M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new OTLK positions and 17 closed out — a net gain of 3 holders — while 16 added to existing stakes and 18 trimmed.

The largest buyer was Vanguard Group, adding an estimated $660K. The largest seller was BlackRock, cutting an estimated $1.44M.

  • 66 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2025, up from 63 in Q1 2025.
  • Funds reported $9.56M of Outlook Therapeutics stock for Q2 2025, up 11% quarter-over-quarter.
  • 20 funds opened new Outlook Therapeutics positions in Q2 2025 and 17 closed out, a net change of +3 holders.
  • The largest Outlook Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $660K added.
  • The largest Outlook Therapeutics seller in Q2 2025 was BlackRock, an estimated $1.44M sold.

Based on aggregated 13F filings for Q2 2025.